Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

OLMA

Olema Pharmaceuticals Inc

Jan 09 • 04:00PM ET

28.08

+2.51 9.82 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX REGN BIIB ONC INCY NBIX EXEL ACAD

| Held by: VTI IWM XBI VXF IWN IBB VTWO SCHA DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.29%	Shs Outstand	68.65M	Perf Week	11.08%
Market Cap	2.01B	Forward P/E	-	EPS next Y	-2.24	Insider Trans	-4.99%	Shs Float	65.84M	Perf Month	5.64%
Enterprise Value	1.69B	PEG	-	EPS next Q	-0.52	Inst Own	75.37%	Short Float	16.85%	Perf Quarter	162.92%
Income	-149.96M	P/S	-	EPS this Y	12.92%	Inst Trans	-2.87%	Short Ratio	2.93	Perf Half Y	503.87%
Sales	0.00M	P/B	6.27	EPS next Y	-17.08%	ROA	-51.48%	Short Interest	11.09M	Perf YTD	12.32%
Book/sh	4.48	P/C	6.11	EPS next 5Y	-3.01%	ROE	-59.22%	52W High	36.26 -22.56%	Perf Year	435.88%
Cash/sh	4.59	P/FCF	-	EPS past 3/5Y	-7.01% -83.00%	ROIC	-48.25%	52W Low	2.86 881.82%	Perf 3Y	1001.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.54% 7.94%	Perf 5Y	-38.53%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.23%	Oper. Margin	-	ATR (14)	2.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.23	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.03	EPS Q/Q	18.40%	SMA20	-1.03%	Beta	1.91	Target Price	45.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	27.69%	Rel Volume	0.67	Prev Close	25.57
Employees	96	LT Debt/Eq	0.01	Earnings	Nov 10 BMO	SMA200	184.80%	Avg Volume	3.78M	Price	28.08
IPO	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.24% -	Trades		Volume	2,541,940	Change	9.82%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Oct-08-25	Initiated	Guggenheim	Buy	$20
Aug-12-25	Reiterated	Citigroup	Buy	$20 → $21
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

Jan-05-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:19AM	Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT (Insider Monkey)
Dec-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 05:45PM	This strategist is 'following the money' on these stock picks (Yahoo Finance Video) +8.11%
04:30PM	Loading…
Nov-21-25 04:30PM	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.27%
Nov-20-25 04:01PM	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.28%
Nov-19-25 11:50AM	Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? (Barchart)
07:00AM	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock (GlobeNewswire)
Nov-18-25 04:51PM	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +136.38%
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
09:20AM	Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% (Investor's Business Daily)
Nov-10-25 07:00AM	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
04:30PM	Loading…
Oct-30-25 04:30PM	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 (GlobeNewswire)
Oct-18-25 03:00AM	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 (GlobeNewswire)
Oct-16-25 04:33PM	Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential (Insider Monkey) -7.43%
Oct-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 11:41AM	Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) (Insider Monkey)
Sep-12-25 10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
Sep-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 07:00AM	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer (GlobeNewswire) +18.50%
Aug-20-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-13-25 01:15AM	Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals (Insider Monkey)
Aug-11-25 04:01PM	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire) +16.19%
Aug-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
07:00AM	Loading…
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.62%
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.01%
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-27-23 12:54PM	Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why (Zacks) -5.79%
11:32AM	This Small Cap Is My Stock Pick, as the Market Shakes Its Hangover (TheStreet.com)
Nov-22-23 09:00AM	Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. (Investor's Business Daily)
Nov-07-23 04:02PM	Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.43%
Nov-02-23 04:32PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.35% +5.40%

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Dec 22 '25	Sale	28.53	2,881	82,195	741,259	Dec 29 09:55 PM
CLARK IAN T	Director	Dec 19 '25	Option Exercise	4.61	264,800	1,219,544	264,800	Dec 23 09:42 PM
CLARK IAN T	Director	Dec 19 '25	Sale	29.73	264,800	7,873,109	0	Dec 23 09:42 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 19 '25	Sale	30.46	51,000	1,553,544	551,881	Dec 23 09:41 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Option Exercise	14.07	50,000	703,392	153,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Option Exercise	15.25	40,000	610,000	173,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Option Exercise	7.02	50,000	351,000	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Sale	28.04	100,000	2,804,000	53,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Sale	27.66	99,509	2,752,419	4,488	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Sale	28.20	70,000	1,973,729	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Officer	Dec 23 '25	Proposed Sale	27.66	99,509	2,752,165		Dec 23 01:31 PM
Harmon Cyrus	Officer	Dec 22 '25	Proposed Sale	28.53	2,881	82,182		Dec 22 04:09 PM
Zojwalla Naseem	Officer	Dec 22 '25	Proposed Sale	28.04	100,000	2,804,039		Dec 22 02:14 PM
Myles David C.	Officer	Dec 19 '25	Proposed Sale	30.46	51,000	1,553,447		Dec 19 04:33 PM
Zojwalla Naseem	Officer	Dec 19 '25	Proposed Sale	28.19	70,000	1,973,561		Dec 19 04:29 PM
CLARK IAN T	Director	Dec 19 '25	Proposed Sale	29.73	264,800	7,873,502		Dec 19 02:35 PM
RAPPAPORT ANDREW	Director	Nov 21 '25	Option Exercise	0.39	35,868	13,989	35,868	Nov 25 06:00 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.33	10,000	83,300	744,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.04	10,000	80,400	754,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.32	3,086	25,676	117,028	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.08	1,914	15,465	120,114	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Proposed Sale	8.33	13,086	108,978		Sep 18 02:08 PM
Harmon Cyrus	Director	Sep 16 '25	Proposed Sale	8.04	11,914	95,827		Sep 16 04:39 PM

Open in Screener

GH

Guardant Health Inc

Jan 09 • 04:00PM ET

110.17

+1.43 1.32 %

Healthcare • Diagnostics & Research • USA • NASD

GH Guardant Health Inc daily Stock Chart

Peers: ILMN QGEN EXAS FLGT BIO SRPT MYGN NTRA CDNA TXG

| Held by: VTI IWM VB VBK VXF IWO ARKG SCHA VTWO CGGR

Index	RUT	P/E	-	EPS (ttm)	-3.21	Insider Own	3.72%	Shs Outstand	125.01M	Perf Week	8.29%
Market Cap	14.07B	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-13.53%	Shs Float	124.45M	Perf Month	6.74%
Enterprise Value	14.81B	PEG	-	EPS next Q	-0.77	Inst Own	96.60%	Short Float	7.92%	Perf Quarter	68.82%
Income	-398.79M	P/S	15.59	EPS this Y	13.45%	Inst Trans	1.79%	Short Ratio	3.91	Perf Half Y	119.24%
Sales	902.57M	P/B	-	EPS next Y	12.27%	ROA	-28.33%	Short Interest	9.85M	Perf YTD	7.86%
Book/sh	-2.84	P/C	24.26	EPS next 5Y	21.93%	ROE	-4584.47%	52W High	113.91 -3.28%	Perf Year	204.76%
Cash/sh	4.54	P/FCF	-	EPS past 3/5Y	3.89% -33.61%	ROIC	-42.18%	52W Low	34.80 216.58%	Perf 3Y	308.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.52% 28.08%	Gross Margin	63.76%	Volatility	6.29% 3.90%	Perf 5Y	-14.52%
Dividend TTM	-	EV/Sales	16.41	EPS Y/Y TTM	24.17%	Oper. Margin	-49.02%	ATR (14)	4.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	30.38%	Profit Margin	-44.18%	RSI (14)	63.88	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	15.15%	SMA20	7.04%	Beta	1.64	Target Price	121.59
Payout	-	Debt/Eq	-	Sales Q/Q	38.50%	SMA50	9.03%	Rel Volume	0.96	Prev Close	108.74
Employees	2021	LT Debt/Eq	-	Earnings	Oct 29 AMC	SMA200	72.17%	Avg Volume	2.52M	Price	110.17
IPO	Oct 04, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.28% 12.56%	Trades		Volume	2,411,043	Change	1.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$105
Dec-02-25	Resumed	Morgan Stanley	Overweight	$130
Sep-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$75
Sep-22-25	Resumed	Wells Fargo	Overweight	$72
Apr-10-25	Initiated	Mizuho	Outperform	$55
Jan-23-25	Initiated	Barclays	Overweight	$60
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy	$36
Jun-03-24	Resumed	Jefferies	Buy	$32
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$36
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $50

Show Previous Ratings

Jan-11-26 05:00PM	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
01:10AM	Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH) (Insider Monkey)
Jan-10-26 08:00AM	Google, Shopify Lead Big 2025 Winners Near New Buy Points (Investor's Business Daily)
Jan-09-26 02:24PM	Clinical Labs Hope to Head Off Looming Medicare Cuts (Barrons.com)
Jan-08-26 01:30PM	Guardant Health Catapults 234%; Sets Up With Strong Sales Outlook (Investor's Business Daily)
10:31AM	Loading…
10:31AM	Cathie Wood Dumps $12.7 Million Worth of Meta Stock Amid Ray-Ban Smart Glasses Delay, Ark Loads Up On This Gaming Platform (Benzinga)
08:05AM	Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families (Business Wire)
Jan-06-26 06:54PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +10.27%
Dec-31-25 11:33AM	Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside (Insider Monkey)
Dec-29-25 04:05PM	Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:59AM	Stock Market Today: Dow Down From Record Highs; Nvidia, Tesla Slide (Live Coverage) (Investor's Business Daily)
Dec-27-25 08:05AM	Palantir, Nvidia Lead 5 Stocks Near Buy Points Heading Into Final Days Of 2025 (Investor's Business Daily)
Dec-26-25 05:23PM	Dow Jones Futures: Tesla, Nvidia Lead 5 Giants In Buy Areas; Market Strong As 2025 Nears End (Investor's Business Daily)
03:41PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-22-25 10:19PM	Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth (Insider Monkey)
10:41AM	Loading…
Dec-16-25 10:41AM	Guardant Health price target raised to $120 from $100 at BofA (TipRanks)
Dec-11-25 08:05AM	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S. (Business Wire)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
08:05AM	Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy (Business Wire)
Dec-08-25 10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
Dec-05-25 06:42PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -5.99%
09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
08:05AM	Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium (Business Wire)
Dec-04-25 09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-03-25 03:27PM	Why Guardant Health (GH) Stock Is Up Today (StockStory)
Nov-24-25 06:40PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +5.53%
Nov-23-25 11:03PM	Guardant Health (GH): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
01:00PM	The marketing guru who helped turn Khosla Ventures into an AI powerhouse is moving on (TechCrunch)
10:34AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron (The Wall Street Journal)
09:41AM	Loading…
09:41AM	Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences (The Wall Street Journal)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-12-25 08:05AM	Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access (Business Wire)
Nov-10-25 08:05AM	Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring (Business Wire)
Nov-07-25 08:00AM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-25 06:35PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:05AM	New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response (Business Wire)
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
Nov-05-25 04:05PM	Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients (Business Wire)
12:26PM	Why Guardant Health (GH) Shares Are Sliding Today (StockStory)
02:15AM	Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering (Business Wire)
02:15AM	Guardant Health Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
12:37AM	The Top 5 Analyst Questions From Guardant Health's Q3 Earnings Call (StockStory)
Nov-04-25 04:39PM	Guardant Health Announces Proposed Public Offering of Common Stock (Business Wire)
04:38PM	Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033 (Business Wire)
Oct-31-25 10:01AM	Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook (Insider Monkey)
05:45AM	Why Guardant Health Was Such an Investor Darling This Week (Motley Fool)
Oct-30-25 07:19PM	Analyst Report: Guardant Health, Inc. (Morningstar Research) +27.87%
06:56PM	Why Guardant Health Stock Surged Today (Motley Fool)
04:13PM	Why IBD 50's Guardant Health, Up 137% in 2025, Just Rocketed Again (Investor's Business Daily)
09:54AM	These Stocks Are Moving the Most Today: Microsoft, Meta, Alphabet, Chipotle, Carvana, FMC, Roblox, Guardant Health, Metsera, and More (Barrons.com)
09:11AM	GH Q3 Deep Dive: Broad-Based Growth, Screening Momentum, and Margin Improvement (StockStory)
Oct-29-25 07:30PM	Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:05PM	Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:18PM	Guardant Health's (NASDAQ:GH) Q3: Strong Sales, Stock Jumps 15.5% (StockStory)
05:03PM	Guardant Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
Oct-27-25 11:10PM	Earnings To Watch: Guardant Health (GH) Reports Q3 Results Tomorrow (StockStory)
09:20AM	Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals (Zacks)
08:05AM	Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights (Business Wire)
Oct-26-25 03:01PM	Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 (Business Wire)
Oct-21-25 03:41PM	Colon Cancer Screening Leader Guardant Health Tests Buy Point As Earnings Loom (Investor's Business Daily)
Oct-20-25 04:24PM	Stock Of The Day: Why IBD 50's Guardant Health Has Rallied 231% In A Month (Investor's Business Daily) +7.24%
Oct-18-25 08:00AM	S&P 500's Walmart In Buy Zone, Leads Five Stocks Near Buy Points (Investor's Business Daily)
08:00AM	S&P 500's New AI Play? Walmart In Buy Zone, Leads Five Stocks To Watch Amid Volatile Market (Investor's Business Daily)
04:16AM	Grail Blood Test Found Seven Times More Cancers Than Standard Tests, Data Show (Barrons.com)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks)
09:35AM	Banks Look To Stabilize After First Brands Bankruptcy Torpedoes Shares (Investor's Business Daily)
08:17AM	Stock Market Today: Dow Falls Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage) (Investor's Business Daily)
Oct-15-25 04:57PM	Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 (Business Wire) +5.11%
Oct-09-25 04:05PM	Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 (Business Wire)
Sep-30-25 12:33PM	Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy (Insider Monkey)
09:05AM	DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute (Zacks)
Sep-29-25 12:15PM	Why Guardant Health (GH) Stock Is Trading Up Today (StockStory)
08:05AM	FDA Approves Guardant360 CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer (Business Wire)
Sep-26-25 11:25AM	Guardants New Blood Test Can Detect Many Different Cancers. The Company Is Promising the Same for Other Diseases. (Barrons.com)
Sep-25-25 02:24PM	Guardant's New Blood Test Can Detect Many Different Cancers. It's Promising the Same for Other Diseases. (Barrons.com)
12:41PM	Guardant Health (GH) Stock Trades Up, Here Is Why (StockStory)
09:00AM	Wolfe Research lifts Guardant Health to Outperform, sees 30% upside (Investing.com)
Sep-24-25 08:05AM	Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield Blood-based Screening Test in the United States (Business Wire)
12:00AM	3 Reasons to Avoid GH and 1 Stock to Buy Instead (StockStory)
Sep-23-25 03:26PM	Guardant Health (GH) Stock Is Up, What You Need To Know (StockStory)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-18-25 11:31PM	Testing & Diagnostics Services Q2 Earnings: Guardant Health (NASDAQ:GH) is the Best in the Biz (StockStory)
Sep-17-25 11:33PM	Q2 Earnings Recap: Guardant Health (NASDAQ:GH) Tops Testing & Diagnostics Services Stocks (StockStory)
Sep-15-25 04:07PM	Alex M. Azar II Joins Guardant Health Board of Directors (Business Wire)
Sep-11-25 05:33PM	More Blood Tests for Cancer Hit the Market (Barrons.com)
08:05AM	Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership (Business Wire)
Sep-10-25 07:03PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Sep-08-25 08:05AM	Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States (Business Wire)
Sep-05-25 05:28AM	Guardant Health reports positive clinical readout update for Shield algorithm (Medical Device Network)
Sep-04-25 12:30PM	What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum? (Zacks) -5.69%
12:16PM	Why Guardant Health (GH) Shares Are Plunging Today (StockStory)
12:16PM	Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run (Investor's Business Daily)
08:06AM	Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test (Business Wire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-28-25 04:05PM	Guardant Health to Host Investor Day on September 24, 2025 (Business Wire)
Aug-26-25 04:05PM	Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-15-25 05:05PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:15AM	TMO Receives FDA Approval for Oncomine Dx Target Test (Zacks)

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monroe Terilyn J.	Chief People Officer	Jan 07 '26	Sale	112.08	10,031	1,124,279	20,990	Jan 09 04:09 PM
Monroe Terilyn J.	Officer	Jan 07 '26	Proposed Sale	112.07	10,031	1,124,200		Jan 07 04:03 PM
Saia John G.	Chief Legal Officer	Jan 01 '26	Option Exercise	0.00	19,046	0	62,703	Jan 05 06:01 PM
Monroe Terilyn J.	Chief People Officer	Jan 01 '26	Option Exercise	0.00	17,555	0	38,545	Jan 05 06:01 PM
Kalia Kumud	Chief Information Officer	Jan 01 '26	Option Exercise	0.00	21,237	0	43,916	Jan 05 06:00 PM
Freeman Chris	Chief Commercial Officer	Jan 01 '26	Option Exercise	0.00	27,237	0	54,032	Jan 05 05:59 PM
EAGLE CRAIG	Chief Medical Officer	Jan 01 '26	Option Exercise	0.00	25,442	0	70,449	Jan 05 05:58 PM
Chudova Darya	Chief Technology Officer	Jan 01 '26	Option Exercise	0.00	22,732	0	29,744	Jan 05 05:57 PM
Bell Michael Brian	Chief Financial Officer	Jan 01 '26	Option Exercise	0.00	23,038	0	52,703	Jan 05 05:57 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,002,689	Jan 05 05:56 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,024,245	Jan 05 05:56 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 31 '25	Option Exercise	0.00	4,815	0	2,051,958	Jan 05 05:55 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jan 01 '26	Option Exercise	0.00	23,997	0	2,073,514	Jan 05 05:55 PM
Krognes Steve E.	Director	Dec 31 '25	Option Exercise	0.00	154	0	18,745	Jan 05 05:54 PM
MIGNONE ROBERTO	Director	Dec 21 '25	Option Exercise	0.00	264	0	3,695	Dec 23 07:25 PM
Hidalgo Medina Manuel	Director	Dec 17 '25	Option Exercise	0.00	232	0	1,029	Dec 18 06:34 PM
Tariq Musa	Director	Dec 17 '25	Sale	101.46	116	11,769	7,993	Dec 18 06:33 PM
Tariq Musa	Director	Dec 15 '25	Option Exercise	0.00	250	0	8,109	Dec 17 07:21 PM
Saia John G.	Chief Legal Officer	Dec 15 '25	Option Exercise	0.00	1,020	0	44,192	Dec 17 07:20 PM
Kalia Kumud	Chief Information Officer	Dec 15 '25	Option Exercise	0.00	637	0	23,002	Dec 17 07:20 PM
Freeman Chris	Chief Commercial Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	27,389	Dec 17 07:19 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Dec 15 '25	Sale	103.82	90,565	9,402,220	2,047,143	Dec 17 07:18 PM
EAGLE CRAIG	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	1,402	0	45,718	Dec 17 07:18 PM
Chudova Darya	Chief Technology Officer	Dec 15 '25	Sale	104.04	5,451	567,132	7,012	Dec 17 07:17 PM
Bell Michael Brian	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	3,272	0	31,324	Dec 17 07:17 PM
Tariq Musa	Director	Dec 17 '25	Proposed Sale	101.46	116	11,769		Dec 17 04:58 PM
Eltoukhy Helmy	Officer	Dec 15 '25	Proposed Sale	103.82	90,565	9,402,223		Dec 15 05:08 PM
Talasaz AmirAli	Co-Chief Executive Officer	Dec 08 '25	Sale	105.05	100,000	10,505,474	168,223	Dec 10 09:33 PM
Kalia Kumud	Chief Information Officer	Dec 08 '25	Sale	104.60	2,000	209,204	22,365	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Option Exercise	32.55	1,000	32,550	2,047	Dec 10 09:32 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Sale	105.00	1,250	131,250	797	Dec 10 09:32 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	105.04	13,664	1,435,227	54,480	Dec 10 09:31 PM
Chudova Darya	Chief Technology Officer	Dec 08 '25	Sale	106.00	9,271	982,753	12,463	Dec 10 09:31 PM
Freeman Chris	Chief Commercial Officer	Dec 05 '25	Sale	103.07	31,452	3,241,621	25,987	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Option Exercise	30.71	56,287	1,728,787	108,414	Dec 08 09:37 PM
Bell Michael Brian	Chief Financial Officer	Dec 05 '25	Sale	103.14	80,362	8,288,742	28,052	Dec 08 09:37 PM
CLARK IAN T	Director	Dec 05 '25	Option Exercise	35.83	28,611	1,025,156	38,462	Dec 08 09:36 PM
CLARK IAN T	Director	Dec 05 '25	Sale	107.19	28,611	3,066,817	9,851	Dec 08 09:36 PM
Talasaz AmirAli	Officer	Dec 08 '25	Proposed Sale	105.05	100,000	10,505,470		Dec 08 05:50 PM
Chudova Darya	Officer	Dec 08 '25	Proposed Sale	105.43	28,780	3,034,203		Dec 08 04:47 PM
Hidalgo Medina Manuel	Director	Dec 08 '25	Proposed Sale	105.00	1,250	131,250		Dec 08 04:46 PM
Kalia Kumud	Officer	Dec 08 '25	Proposed Sale	104.60	2,000	209,204		Dec 08 04:44 PM
Freeman Chris	Officer	Dec 05 '25	Proposed Sale	103.07	31,452	3,241,621		Dec 05 05:22 PM
CLARK IAN T	Director	Dec 05 '25	Proposed Sale	107.19	28,611	3,066,818		Dec 05 05:21 PM
Bell Michael Brian	Officer	Dec 05 '25	Proposed Sale	103.14	80,362	8,288,741		Dec 05 05:20 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Option Exercise	22.68	50,000	1,134,050	76,087	Dec 03 09:30 PM
Monroe Terilyn J.	Chief People Officer	Dec 01 '25	Sale	105.97	55,167	5,846,163	20,920	Dec 03 09:30 PM
Krognes Steve E.	Director	Nov 30 '25	Option Exercise	0.00	155	0	18,591	Dec 01 09:41 PM
Monroe Terilyn J.	Officer	Dec 01 '25	Proposed Sale	105.97	55,167	5,846,164		Dec 01 04:56 PM
MIGNONE ROBERTO	Director	Nov 21 '25	Option Exercise	0.00	264	0	3,431	Nov 24 06:21 PM
Tariq Musa	Director	Nov 19 '25	Sale	96.25	116	11,165	7,859	Nov 20 09:27 PM
Tariq Musa	Director	Nov 19 '25	Proposed Sale	96.25	116	11,165		Nov 19 04:01 PM
Hidalgo Medina Manuel	Director	Nov 17 '25	Option Exercise	0.00	232	0	1,047	Nov 18 05:07 PM
Tariq Musa	Director	Nov 15 '25	Option Exercise	0.00	250	0	7,975	Nov 17 05:30 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Option Exercise	32.55	1,000	32,550	2,315	Nov 10 07:18 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Sale	95.19	1,500	142,780	815	Nov 10 07:18 PM
Saia John G.	Chief Legal Officer	Nov 07 '25	Sale	96.25	8,996	865,865	43,172	Nov 10 07:17 PM
Hidalgo Medina Manuel	Director	Nov 07 '25	Proposed Sale	95.19	1,500	142,780		Nov 07 04:25 PM
Saia John G.	Officer	Nov 07 '25	Proposed Sale	96.25	8,996	865,865		Nov 07 04:21 PM
Krognes Steve E.	Director	Oct 31 '25	Option Exercise	0.00	154	0	18,436	Nov 03 05:45 PM
MIGNONE ROBERTO	Director	Oct 21 '25	Option Exercise	0.00	3,167	0	3,167	Oct 22 07:07 PM
Hidalgo Medina Manuel	Director	Oct 17 '25	Option Exercise	0.00	232	0	1,315	Oct 20 07:50 PM
Tariq Musa	Director	Oct 17 '25	Sale	66.95	116	7,766	7,725	Oct 20 07:49 PM
POTTER MYRTLE S	Director	Oct 17 '25	Sale	66.95	26	1,741	18,324	Oct 20 07:48 PM
Tariq Musa	Director	Oct 17 '25	Proposed Sale	66.95	116	7,766		Oct 17 04:02 PM
POTTER MYRTLE S	Director	Oct 17 '25	Proposed Sale	66.96	26	1,741		Oct 17 04:00 PM
Tariq Musa	Director	Oct 15 '25	Option Exercise	0.00	250	0	7,841	Oct 16 09:13 PM
POTTER MYRTLE S	Director	Oct 15 '25	Option Exercise	0.00	69	0	18,350	Oct 16 09:11 PM
Saia John G.	Chief Legal Officer	Oct 01 '25	Option Exercise	0.00	14,167	0	59,599	Oct 02 08:06 PM
Monroe Terilyn J.	Chief People Officer	Oct 01 '25	Option Exercise	0.00	10,477	0	31,397	Oct 02 08:05 PM
Kalia Kumud	Chief Information Officer	Oct 01 '25	Option Exercise	0.00	10,549	0	29,713	Oct 02 08:05 PM
Freeman Chris	Chief Commercial Officer	Oct 01 '25	Option Exercise	0.00	13,550	0	63,179	Oct 02 08:05 PM
EAGLE CRAIG	Chief Medical Officer	Oct 01 '25	Option Exercise	0.00	13,859	0	51,341	Oct 02 08:04 PM
Chudova Darya	Chief Technology Officer	Oct 01 '25	Option Exercise	0.00	16,104	0	97,553	Oct 02 08:04 PM
Bell Michael Brian	Chief Financial Officer	Oct 01 '25	Option Exercise	0.00	15,181	0	59,822	Oct 02 08:04 PM
Talasaz AmirAli	Co-Chief Executive Officer	Sep 30 '25	Option Exercise	0.00	4,814	0	1,988,479	Oct 02 08:03 PM
Talasaz AmirAli	Co-Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	23,997	0	2,010,036	Oct 02 08:03 PM
Krognes Steve E.	Director	Sep 30 '25	Option Exercise	0.00	154	0	18,282	Oct 02 08:03 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Sep 30 '25	Option Exercise	0.00	4,814	0	2,128,313	Oct 02 08:01 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Oct 01 '25	Option Exercise	0.00	23,997	0	2,149,870	Oct 02 08:01 PM
Hidalgo Medina Manuel	Director	Sep 17 '25	Option Exercise	0.00	232	0	1,083	Sep 18 04:33 PM
Tariq Musa	Director	Sep 15 '25	Option Exercise	0.00	249	0	7,707	Sep 17 05:17 PM
Tariq Musa	Director	Sep 17 '25	Sale	55.63	116	6,453	7,591	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 15 '25	Option Exercise	0.00	68	0	18,307	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 17 '25	Sale	55.63	26	1,446	18,281	Sep 17 05:17 PM
Saia John G.	Chief Legal Officer	Sep 15 '25	Option Exercise	0.00	1,019	0	45,967	Sep 17 05:16 PM
Kalia Kumud	Chief Information Officer	Sep 15 '25	Option Exercise	0.00	638	0	19,488	Sep 17 05:15 PM
Freeman Chris	Chief Commercial Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	50,223	Sep 17 05:15 PM
EAGLE CRAIG	Chief Medical Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	38,193	Sep 17 05:14 PM
Bell Michael Brian	Chief Financial Officer	Sep 15 '25	Option Exercise	0.00	3,272	0	46,300	Sep 17 05:13 PM
POTTER MYRTLE S	Director	Sep 17 '25	Proposed Sale	55.62	26	1,446		Sep 17 04:17 PM
Tariq Musa	Director	Sep 17 '25	Proposed Sale	55.63	116	6,453		Sep 17 04:16 PM
Hidalgo Medina Manuel	Director	Sep 12 '25	Sale	54.16	2,165	117,251	851	Sep 15 05:09 PM
Hidalgo Medina Manuel	Director	Sep 12 '25	Proposed Sale	54.16	2,165	117,251		Sep 12 04:25 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Sep 09 '25	Sale	59.45	300,000	17,835,995	2,123,499	Sep 11 07:14 PM
Eltoukhy Helmy	Officer	Sep 09 '25	Proposed Sale	59.45	300,000	17,835,990		Sep 09 05:32 PM
Joyce Meghan V.	Director	Sep 02 '25	Sale	65.84	100	6,584	11,183	Sep 03 06:50 PM
Saia John G.	Chief Legal Officer	Sep 01 '25	Option Exercise	0.00	264	0	45,087	Sep 03 06:47 PM
Kalia Kumud	Chief Information Officer	Sep 01 '25	Option Exercise	0.00	711	0	19,211	Sep 03 06:46 PM
Chudova Darya	Chief Technology Officer	Sep 01 '25	Option Exercise	0.00	316	0	81,610	Sep 03 06:44 PM

OLMA

Olema Pharmaceuticals Inc

GH

Guardant Health Inc

Upgrade your FINVIZ experience